The transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cells
Authors:
- Tracie DelgadoTracie Delgado
- Gustavo HelgueraGHGustavo Helguera
- Manuel L. PenichetMPManuel L. Penichet
- 1 November 2006
- journal article
- review article
- Published by Elsevier in Clinical Immunology
- Vol. 121 (2) , 159-176
Abstract
No abstract availableKeywords
This publication has 86 references indexed in Scilit:
- The p53 Tumor Suppressor Gene and Nuclear Protein: Basic Science Review and Relevance in the Management of Bladder CancerJournal of Urology, 2003
- p53 and PTEN/MMAC1/TEP1 Gene Therapy of Human Prostate PC-3 Carcinoma Xenograft, Using Transferrin-Facilitated Lipofection Gene Delivery StrategyHuman Gene Therapy, 2002
- Liposomal Drug FormulationsDrugs, 1998
- Overproduction of fungal ribotoxin α-sarcin in Escherichia coli: generation of an active immunotoxinGene, 1997
- The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cellsBiochimica et Biophysica Acta (BBA) - Reviews on Biomembranes, 1997
- Generation of Active Immunotoxins Containing Recombinant RestrictocinBiochemical and Biophysical Research Communications, 1996
- In Vitro Cytotoxicities and In Vivo Distribution of Transferrin–Platinum(II) ComplexJournal of Pharmaceutical Sciences, 1995
- Adriamycin(hydrazone)-antibody conjugates require internalization and intracellular acid hydrolysis for antitumor activityCancer Immunology, Immunotherapy, 1991
- Characterization of a translation inhibitory protein from Luffa aegyptiacaBiochemical and Biophysical Research Communications, 1989
- Mutations in Diphtheria Toxin Separate Binding from Entry and Amplify Immunotoxin SelectivityScience, 1987